Researchers are encouraged to consult peer-reviewed literature and experimental studies for detailed methodologies and findings relating to this compound
Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)
It is not approved for human or veterinary use
In the SUSTAIN-6 trial, injectable semaglutide demonstrated a notable effect in reducing the incidence of nonfatal stroke (hazard ratio [HR] 0.61
Weight loss in this phase tends to be modest, often between 1 and 3 pounds
Diabetes Care (2010) 33(9):20746.10.2337/dc10-0200 72 VetterMLWaddenTATeffKLKhanZFCarvajalRRitterSet alGLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification